SCHEMBL3011114

SCHEMBL3011114

O=S(=O)(c1cc(C(F)(F)F)ccc1Cl)N1CCN(c2nc(-c3ccc(F)c(F)c3)cs2)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.52
ALDH1A1 P00352 3/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
MAPT P10636 5/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
LMNA P02545 3/20 0.50
TSHR P16473 1/20 0.50
ATM Q13315 1/20 0.50
MAPK1 P28482 4/20 0.48
RAB9A P51151 2/20 0.47
AR P10275 2/20 0.46
USP2 O75604 1/20 0.45
RECQL P46063 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ALOX5AP P20292 2/20 0.42
FEN1 P39748 2/20 0.42
NPC1 O15118 1/20 0.40
GPR6 P46095 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012132 0.95 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1L3MBTL1MAPTMEN1
SCHEMBL3003681 0.94 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1L3MBTL1MAPTMEN1
SCHEMBL3772669 0.94 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1L3MBTL1MAPTMEN1
SCHEMBL3013011 0.92 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1L3MBTL1MAPTMEN1
SCHEMBL3011631 0.92 AR (0.54) SMN1; SMN2ALDH1A1L3MBTL1MAPTMEN1
SCHEMBL3010918 0.90 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1L3MBTL1MAPTMEN1
SCHEMBL3009026 0.89 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1L3MBTL1MAPTMEN1
SCHEMBL3003896 0.89 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1L3MBTL1MAPTMEN1
SCHEMBL3018558 0.88 AR (0.44) SMN1; SMN2ALDH1A1L3MBTL1MAPTMEN1
SCHEMBL3009558 0.88 MEN1 (0.49) SMN1; SMN2ALDH1A1L3MBTL1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.